154 related articles for article (PubMed ID: 38021444)
1. GW4869 Can Inhibit Epithelial-Mesenchymal Transition and Extracellular HSP90α in Gefitinib-Sensitive NSCLC Cells.
Wan X; Fang Y; Du J; Cai S; Dong H
Onco Targets Ther; 2023; 16():913-922. PubMed ID: 38021444
[TBL] [Abstract][Full Text] [Related]
2. DCLK1 Drives EGFR-TKI-Acquired Resistance in Lung Adenocarcinoma by Remodeling the Epithelial-Mesenchymal Transition Status.
Yan R; Huang X; Liu H; Xiao Z; Liu J; An G; Ge Y
Biomedicines; 2023 May; 11(5):. PubMed ID: 37239162
[TBL] [Abstract][Full Text] [Related]
3.
Hu C; Zhou A; Hu X; Xiang Y; Huang M; Huang J; Yang D; Tang Y
Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36362025
[TBL] [Abstract][Full Text] [Related]
4. STAT3 inhibitor BBI608 enhances the antitumor effect of gefitinib on EGFR-mutated non-small cell lung cancer cells.
Wang Q; Lu B; Zhang Y; Yu J; Guo J; Zhou Q; Lv H; Sun Y
Hum Cell; 2021 Nov; 34(6):1855-1865. PubMed ID: 34370268
[TBL] [Abstract][Full Text] [Related]
5. Pedunculoside inhibits epithelial-mesenchymal transition and overcomes Gefitinib-resistant non-small cell lung cancer through regulating MAPK and Nrf2 pathways.
Fan Q; Liang X; Xu Z; Li S; Han S; Xiao Y; Xu Q; Yuan R; Yang S; Gao H
Phytomedicine; 2023 Jul; 116():154884. PubMed ID: 37209605
[TBL] [Abstract][Full Text] [Related]
6. Chronic treatment of non-small-cell lung cancer cells with gefitinib leads to an epigenetic loss of epithelial properties associated with reductions in microRNA-155 and -200c.
Narita M; Shimura E; Nagasawa A; Aiuchi T; Suda Y; Hamada Y; Ikegami D; Iwasawa C; Arakawa K; Igarashi K; Kuzumaki N; Yoshioka Y; Ochiya T; Takeshima H; Ushijima T; Narita M
PLoS One; 2017; 12(2):e0172115. PubMed ID: 28225782
[TBL] [Abstract][Full Text] [Related]
7. The canonical TGF-β/Smad signalling pathway is involved in PD-L1-induced primary resistance to EGFR-TKIs in EGFR-mutant non-small-cell lung cancer.
Zhang Y; Zeng Y; Liu T; Du W; Zhu J; Liu Z; Huang JA
Respir Res; 2019 Jul; 20(1):164. PubMed ID: 31331328
[TBL] [Abstract][Full Text] [Related]
8. Reciprocal positive regulation between Cx26 and PI3K/Akt pathway confers acquired gefitinib resistance in NSCLC cells via GJIC-independent induction of EMT.
Yang J; Qin G; Luo M; Chen J; Zhang Q; Li L; Pan L; Qin S
Cell Death Dis; 2015 Jul; 6(7):e1829. PubMed ID: 26203858
[TBL] [Abstract][Full Text] [Related]
9. Mechanism research of miR-34a regulates Axl in non-small-cell lung cancer with gefitinib-acquired resistance.
Xiong R; Sun XX; Wu HR; Xu GW; Wang GX; Sun XH; Xu MQ; Xie MR
Thorac Cancer; 2020 Jan; 11(1):156-165. PubMed ID: 31777195
[TBL] [Abstract][Full Text] [Related]
10. Combination of Gefitinib and Pemetrexed Prevents the Acquisition of TKI Resistance in NSCLC Cell Lines Carrying EGFR-Activating Mutation.
La Monica S; Madeddu D; Tiseo M; Vivo V; Galetti M; Cretella D; Bonelli M; Fumarola C; Cavazzoni A; Falco A; Gervasi A; Lagrasta CA; Naldi N; Barocelli E; Ardizzoni A; Quaini F; Petronini PG; Alfieri R
J Thorac Oncol; 2016 Jul; 11(7):1051-63. PubMed ID: 27006151
[TBL] [Abstract][Full Text] [Related]
11. Sensitization of Non-Small Cell Lung Cancer Cells to Gefitinib and Reversal of Epithelial-Mesenchymal Transition by Aloe-Emodin
Peng M; Zheng Z; Chen S; Fang L; Feng R; Zhang L; Tang Q; Liu X
Front Oncol; 2022; 12():908031. PubMed ID: 35677158
[TBL] [Abstract][Full Text] [Related]
12. Cause-and-Effect relationship between FGFR1 expression and epithelial-mesenchymal transition in EGFR-mutated non-small cell lung cancer cells.
Vad-Nielsen J; Gammelgaard KR; Daugaard TF; Nielsen AL
Lung Cancer; 2019 Jun; 132():132-140. PubMed ID: 31097086
[TBL] [Abstract][Full Text] [Related]
13. [FOXC1 Knockdown Reverses Gefitinib Resistance in Non-small Cell Lung Cancer].
Peng C; Li P; Yang M; Chen D; Huang Y
Zhongguo Fei Ai Za Zhi; 2021 Aug; 24(8):538-547. PubMed ID: 34334155
[TBL] [Abstract][Full Text] [Related]
14. Mechanistic Insights into Yifei Sanjie Pill's Regulation of EMT to Enhance Gefitinib Treatment effect in NSCLC by in silico analysis and experimental validation.
Zhou R; Qin B; Zhuang Z; Li J; Tiangi Gao YS; Wu D; Yuan Y; Tang Y; Lin L
J Ethnopharmacol; 2024 May; ():118343. PubMed ID: 38750985
[TBL] [Abstract][Full Text] [Related]
15. Gefitinib promotes CXCR4-dependent epithelial to mesenchymal transition via TGF-β1 signaling pathway in lung cancer cells harboring EGFR mutation.
Zhu Q; Zhang Z; Lu C; Xu F; Mao W; Zhang K; Shou H; Liu Z; Gu J; Ge D
Clin Transl Oncol; 2020 Aug; 22(8):1355-1363. PubMed ID: 31900845
[TBL] [Abstract][Full Text] [Related]
16. The miR‑625‑3p/AXL axis induces non‑T790M acquired resistance to EGFR‑TKI via activation of the TGF‑β/Smad pathway and EMT in EGFR‑mutant non‑small cell lung cancer.
Du W; Sun L; Liu T; Zhu J; Zeng Y; Zhang Y; Wang X; Liu Z; Huang JA
Oncol Rep; 2020 Jul; 44(1):185-195. PubMed ID: 32319651
[TBL] [Abstract][Full Text] [Related]
17. Reverse epithelial-mesenchymal transition contributes to the regain of drug sensitivity in tyrosine kinase inhibitor-resistant non-small cell lung cancer cells.
Lee AF; Chen MC; Chen CJ; Yang CJ; Huang MS; Liu YP
PLoS One; 2017; 12(7):e0180383. PubMed ID: 28683123
[TBL] [Abstract][Full Text] [Related]
18. Targeting c-kit inhibits gefitinib resistant NSCLC cell growth and invasion through attenuations of stemness, EMT and acquired resistance.
Zhou Y; Wang L; Sun Z; Zhang J; Wang X
Am J Cancer Res; 2020; 10(12):4251-4265. PubMed ID: 33414998
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic silencing of miR-483-3p promotes acquired gefitinib resistance and EMT in EGFR-mutant NSCLC by targeting integrin β3.
Yue J; Lv D; Wang C; Li L; Zhao Q; Chen H; Xu L
Oncogene; 2018 Aug; 37(31):4300-4312. PubMed ID: 29717264
[TBL] [Abstract][Full Text] [Related]
20. Zinc-finger E-box-binding homeobox 1 (ZEB1) plays a crucial role in the maintenance of lung cancer stem cells resistant to gefitinib.
Nurwidya F; Takahashi F; Winardi W; Tajima K; Mitsuishi Y; Murakami A; Kobayashi I; Nara T; Hashimoto M; Kato M; Hidayat M; Suina K; Hayakawa D; Asao T; Ko R; Shukuya T; Yae T; Shimada N; Yoshioka Y; Sasaki S; Takahashi K
Thorac Cancer; 2021 May; 12(10):1536-1548. PubMed ID: 33764690
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
